Arixon® (Ceftriaxone) is a 3rd generation parenteral Cephalosporin. It is highly stable to most beta-lactamase, both Penicillinases and Cephalosporinases of Gram-positive and Gram-negative bacteria. The action of Arixon is bactericidal which inhibits the cell wall synthesis. Arixon is indicated for pneumonia, typhoid, UTI, otitis media, gonorrhea, chancroid, syphilis, SSTI, UTI, meningitis, prophylaxis of post-operative infections, septicemia, infections in cancer patients and miscellaneous bacterial infections.
Azithrocin® contains Azithromycin U.S.P. It is an azalide antibiotics active against Gram-positive and gram negative organisms. Azithrocin® (Azithromycin) in indicated for infections caused by susceptible organisms; In lower respiratory tract infections including bronchitis and pneumonia, skin and soft tissue infections, otitis media and in upper respiratory tract infections including sinusitis, pharyngitis and tonsillitis. In sexually transmitted disease in men and women Azithrocin® (Azithromycin) is indicated in the treatment of uncomplicated genital infections due to Chlamydia trachomatis. Azithrocin® has very simple once daily dosage schedule for 3 days only, which is very convenient for the patients.
Evo® (Levofloxacin) is a synthetic, broad-spectrum antibacterial agent. Chemically Levofloxacin is a chiral fluorinated carboxyquinolone. It is a second generation fluoroquinolone antibiotic with extended antibacterial spectrum. Evo® acts by inhibiting the DNA gyrase & Topoisomerase IV enzymes. DNA gyrase is involved in the replication, transcription and repair of bacterial DNA where as Topoisomerase IV plays key role in partitioning of the chromosomal DNA during bacterial cell division. Evo® is indicated for the disease conditions like Acute maxillary sinusitis, Acute bacterial exacerbation of chronic bronchitis, Community acquired pneumonia, Nosocomial pneumonia, Uncomplicated & complicated urinary tract infections, Acute pyelonephritis, Uncomplicated & complicated skin and skin structure infections, Chronic bacterial prostatitis etc.
Maxidim (Ceftazidime) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negative bacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa. Maxidim is highly effective in nosocomial infections and drug of choice in pseudomonas infections.
Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria than third-generation cephalosporin. Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus and multiple drug resistant Streptococcus pneumoniae. A particular strength is its activity against Enterobacteriaceae, whereas other cephalosporins are degraded by many plasmid and chromosome-mediated beta-lactamases. Cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected. Cefepime is usually reserved to treat moderate-severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
Triocim® (Cefixime) is a broad spectrum cephalosporin antibiotic of third generation for oral administration. It is a bactericidal antibiotic and is stable to hydrolysis by many beta-lactamases. It is indicated in Enteric fever, Upper and lowers respiratory tract infections, Urinary tract infections, Gonococcal urethritis, and acute otitis media. It can be administered as a single dose or in two divided doses.
Cefuroxime Axetil is a semi-synthetic, broad-spectrum cephalosporin antibiotic for oral administration. Its molecular formula is C20H22N4O10S, and it has a molecular weight of 510.48. Cefuroxime Axetil is in the amorphous form. Cefuroxime Axetil is an orally active prodrug of Cefuroxime. After oral administration, Cefuroxime Axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to release Cefuroxime into the blood stream. Conversion to Cefuroxime, the microbiologically active form, occurs rapidly. The inherent properties of Cefuroxime are unaltered after its administration as Cefuroxime Axetil. Cefuroxime exerts its bactericidal effect by binding to an enzyme or enzymes referred to as penicillin-binding proteins (PBPs) involved in bacterial cell wall synthesis. This binding results in inhibition of bacterial cell wall synthesis and subsequent cell death. Specifically, Cefuroxime shows high affinity for PBP 3, a primary target for Cefuroxime in gram-negative organisms such as E. coli.
TYCLAV® (375 mg, 625 mg and 1 g tablet) is an antibacterial combination consisting of amoxicillin and the beta-lactamase inhibitor, clavulanate potassium. Amoxicillin is a semisynthetic antibiotic with in vitro bactericidal activity against Gram-positive and Gram-negative bacteria. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins.
The formulation of amoxicillin and clavulanic acid in TYCLAV protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin.